Research

Our mission is to fill the gap in LGSOC research funding and drive advancements that will lead to better diagnostic tools, novel therapies, and ultimately, a cure for LGSOC.

We recognize the critical need for dedicated research into LGSOC.

STAAR Funded Research

Thanks to our donors, beginning in 2021 STAAR has been able to award multiple research grants to institutions working to improve outcomes for those with low-grade serous ovarian carcinoma.

LGSOC News

STAAR is a leading advocate for the LGSOC community, driving national attention to a rare cancer that has long been overlooked. From organizing the first-ever Externally Led Patient-Focused Drug Development (EL-PFDD) meeting for LGSOC and hosting the first national LGSOC conference, to earning recognition and awards for innovative awareness campaign, STAAR continues to elevate patient voices and push for meaningful change in research, treatment, and awareness.

STAAR's Research Program

We were the first organization in the United States solely committed to funding and supporting groundbreaking research specifically for low-grade serous ovarian cancer.

By focusing exclusively on this rare disease, STAAR brings hope and improved outcomes to patients who have long been underserved by the medical community.

What we have funded

Because STAAR’s mission centers on accelerating life-saving research for low-grade serous ovarian cancer (LGSOC), we are proud to have raised and funded nearly $1 million in research support. These vital dollars have been directed to leading institutions across the country, advancing innovative studies, expanding clinical insights, and pushing the field closer to better treatments and improved outcomes for women facing this rare cancer.

2021

Project title: Estrogen Signaling in Low-Grade Serous Carcinoma (LGSOC)

Research Institute: MD Anderson Cancer Center
Lead Researcher: Dr. KK Wong PhD, Professor
Start date: June 2021
Project cost: $70,000